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Sepsis is characterized by an uncontrolled inflammatory response to invading microorganisms. We describe
the inflammatory mRNA profiles in whole-blood leukocytes, monocytes, and granulocytes using a multigene
system for 35 inflammatory markers that included pro- and anti-inflammatory cytokines, chemokines, and
signal transduction molecules in a case-control study with 34 patients with sepsis caused by the gram-negative
bacterium Burkholderia pseudomallei (the pathogen causing melioidosis) and 32 healthy volunteers. Relative to
healthy controls, patients with sepsis showed increased transcription of a whole array of inflammatory genes
in peripheral blood leukocytes, granulocytes, and monocytes. Specific monocyte and granulocyte mRNA
profiles were identified. Strong correlations were found between inflammatory mRNA expression levels in
monocytes and clinical outcome. These data underline the notion that circulating leukocytes are an important
source for inflammatory mediators in patients with gram-negative sepsis. Gene profiling such as was done here
provides an excellent tool to obtain insight into the extent of inflammation activation in patients with severe
infection.
Melioidosis is caused by the gram-negative bacillus Burk-
holderia pseudomallei and is an important cause of severe sep-
sis in southeast Asia and northern Australia (4, 23). The most
feared clinical picture is melioidosis septic shock, which is
often associated with pneumonia, bacterial dissemination to
distant sites, and a high mortality. Not surprisingly, melioidosis
is regarded as an excellent model to study gram-negative sepsis
(17): melioidosis is prevalent among rice farmers in southeast
Asia (a relatively homogenous population) and is acquired in a
community setting, patients present in large numbers to a
single institution, and melioidosis is caused by a single organ-
ism and is associated with a high mortality rate.
Sepsis is defined as the systemic inflammatory response to
infection and is one of the leading causes of death in the
western world (15). It has been well established that an uncon-
trolled activation of the inflammatory system in response to an
invading pathogen can result in multiorgan failure and even-
tually death. Activation of leukocytes and activation of the
cytokine and chemokine networks are prominent features of
the septic response. However, knowledge about the nature of
this acute inflammatory state and the role of circulating leu-
kocytes is limited. Most studies on the role of inflammation in
sepsis have focused on the plasma levels of inflammatory me-
diators, most notably cytokines. However, plasma protein lev-
els do not fully reflect the inflammatory signature of leukocytes
in whole blood. Furthermore, tissue leukocytes and parenchy-
mal cells may contribute to the plasma levels of inflammatory
mediators. To date, little work has been devoted to leukocyte
mRNA expression profiles in patients with sepsis. Preliminary
studies using real-time reverse transcription-PCR or gene ar-
rays have suggested activation of multiple pathways in whole-
blood leukocytes obtained from septic patients (13, 14). These
investigations did not provide insights into the relative contri-
butions of monocytes and granulocytes in the systemic inflam-
matory response. To overcome these obstacles in assessing the
inflammatory status of circulating leukocyte subsets, we made
use of a sensitive quantitative assay that is capable of measur-
ing a panel of mRNA levels in a large series of samples in a
single reaction. Target genes included those for pro- and anti-
inflammatory cytokines, chemokines, their receptors, and nu-
clear factor B (NF-B) pathway components. We used this
novel high-throughput technology to characterize the inflam-
matory mRNA profiles in monocytes and granulocytes of pa-
tients with sepsis caused by B. pseudomallei.
MATERIALS AND METHODS
Patients and control subjects. Patients were recruited prospectively at Sap-
prasithiprasong Hospital, Ubon Ratchathani, northeast Thailand, in 2004. Sepsis
due to melioidosis was defined as culture positivity for B. pseudomallei from any
clinical sample plus a systemic inflammatory response syndrome (10). To meet
the systemic inflammatory response syndrome criteria, patients had to meet at
least three of the following four criteria: a core temperature of 38°C or 36°C;
a heart rate of 90 beats/min; a respiratory rate of 20 breaths/min, a PaCO2 of
32 mmHg, or the use of mechanical ventilation for an acute respiratory pro-
cess; and a white cell count of 12  109/liter or 4  109/liter or a differential
count showing10% immature neutrophils. These definitions have been used in
large clinical trials and were modified according to the latest revisions (1, 10).
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Meibergdreef 9, Room G2-132, 1105 AZ Amsterdam, The Netherlands.
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Exclusion criteria were the use of dialysis and/or immunosuppressive therapy,
known disorders of coagulation, and concomitant infection with human immu-
nodeficiency virus. Blood samples were drawn within 36 h after the start of
therapy. Healthy blood donors recruited from the Sapprasithiprasong Hospital
blood bank served as a control population. The study was approved by both the
Ministry of Public Health, Royal Government of Thailand, and the Oxford
Tropical Research Ethics Committee, University of Oxford, England, and writ-
ten informed consent was obtained from all study subjects.
RNA analysis using MLPA. Heparin blood samples were drawn from the
antecubital vein and immediately put on ice. Leukocytes were isolated using
erylysis buffer. Monocyte- and granulocyte-enriched populations where isolated
using Polymorphprep (Axis-Shield, Dundee, United Kingdom). Monocyte and
granulocyte fractions were98% pure as determined by their scatter patterns on
flow cytometry. After isolation, leukocytes, monocytes, and granulocytes were
dissolved in Trizol and stored at 80°C until used for RNA isolation. RNA was
isolated and analyzed by multiplex ligation-dependent probe amplification
(MLPA) as previously described (11, 16, 19, 22). The inflammatory genes as
analyzed by MLPA are listed in Table 1. This MLPA profiling method is insen-
sitive to the total amount of mRNA that is included in the reaction; therefore,
the profile is independent of the total cell count. All samples were tested with the
same batch of reagents. The levels of mRNA for each gene were expressed as a
normalized ratio of the peak area divided by the peak area of the 2-microglobu-
lin (B2M) control gene, resulting in the relative abundances of mRNAs of the
genes of interest (11, 16, 19, 22).
Statistical analysis. Values are expressed as means  standard errors of the
means. Differences between groups were analyzed by the Mann-Whitney U test.
These analyses were performed using GraphPad Prism version 4.00, GraphPad
Software (San Diego, CA). P values of 0.05 were considered statistically sig-
nificant.
RESULTS
Patient characteristics. Thirty-four patients with sepsis
caused by B. pseudomallei (17 males) and 32 healthy control
subjects (22 males) were enrolled. The mean ages were 52
years (range, 18 to 86 years) and 41 years (range, 21 to 59) for
patients and controls, respectively. B. pseudomallei was cul-
tured from body material from all patients; blood cultures were
positive for B. pseudomallei in 21 patients (61.7%), throat swab
or tracheal suction cultures were positive in 13 patients
(38.0%), sputum cultures were positive in 7 patients (21.0%),
cultures of pus from abscess were positive in 8 patients
(23.5%), and urine cultures were positive in 5 patients (14.7%).
After inclusion all patients received appropriate antimicrobial
therapy. The overall in-hospital patient mortality was 44%.
Profiles of mRNAs for genes encoding proinflammatory cy-
tokines and mediators. To determine the inflammatory mRNA
pattern in sepsis caused by B. pseudomallei, MLPA was per-
formed on mRNAs isolated from unfractionated leukocytes
and monocyte- and granulocyte-enriched populations. All the
mRNAs analyzed are listed in Table 1 (see also Materials and
Methods). Table 2 shows the mRNAs encoding proinflamma-
tory cytokines and mediators, In whole-blood leukocytes, sep-
sis caused by B. pseudomallei was characterized by an increased
expression of mRNAs for numerous cytokines (interleukin-1
[IL-1], IL-6, IL-15, gamma interferon [IFN-	], tumor necro-
sis factor alpha [TNF-
], and TNF-) and chemokines (mac-
rophage inflammatory protein 1
 [MIP-1
] and MIP-1) (for
all, P 0.01 to 0.001 versus controls), while it did not influence
the expression of IL-8 or IL-12. In order to determine the
relative contributions of monocytes and granulocytes to this
inflammatory mRNA profile, monocyte- and granulocyte-en-
riched populations were separately analyzed. Monocytes were
shown to be the primary source for several cytokines and
chemokines, most notably for TNF-
, TNF-, IL-15, MIP-1
,
and MIP-1. In the monocyte population, there was no differ-
ence in expression of IL-6, IL-12, IL-1, and monocyte che-
moattractant protein 2 (MCP-2) between patients and con-
trols. In addition, reduced mRNA levels for IL-8, MCP-1, and
TNF- in the monocytes of patients compared to controls were
seen (for all, P  0.05 to 0.01 versus controls). The contribu-
tion of granulocytes to this inflammatory mRNA profile in
whole blood was characterized by an increased expression of
IL-1, IL-6, IL-8, and IL-15 (P  0.01 to 0.001 versus con-
trols), while the expression of the other analyzed proinflam-
matory cytokines and mediators was not influenced. IFN-	
mRNA levels were modestly increased in total leukocytes but
not in either monocyte- or granulocyte-enriched fractions.
Profiles of mRNAs for genes encoding anti-inflammatory
cytokines and mediators. Of note, together with the upregu-
lation of the proinflammatory cytokines, a similar upregulation
of the anti-inflammatory cytokines was observed (Table 3).
Patients showed increased whole-blood leukocyte IL-4, IL-10,
TABLE 1. Inflammatory genes analyzed by MLPA
Functional category and gene product
Cytokines
IL-1

IL-1
IL-1RA
IL-2
IL-4 transcript variant 1
IL-4 transcript variant 2
IL-6
IL-10
IL-12
 (p35)
IL-12 (p40)
IL-13
IL-15-R01
IL-15-R02
TNF-

TNF- ( lymphotoxin alpha)
TNF receptor superfamily 1A
Chemokines
IL-8
MCP-1
MCP-2
MIP-1

MIP-1
Signal transduction
NF-B1
NF-B2
IB
 (NF-B inhibitor alpha)
Others
BMI-1 oncogene homolog
Cyclin-dependent kinase inhibitor 1A
GSTP1
v-Myc oncogene homolog
Phosphodiesterase 4B, cyclic AMP specific
PDGFB
Protein-tyrosine phosphatase, type 4A, 2
Protein-tyrosine phosphatase, nonreceptor type, 1
SERPINB9
Thrombospondin 1
TF
B2M
Polyadenylate-specific RNase
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IL-1 receptor antagonist (IL-1RA), and TNF receptor 1
mRNA levels compared to controls (for all, P  0.0.001 versus
controls). The contribution of monocytes to this anti-inflam-
matory mRNA profile in whole blood was characterized by an
increased expression of IL-4, IL-10, IL-1RA, and TNF recep-
tor 1 (P 0.01 to 0.001 versus controls), while the granulocytes
showed increased IL-1RA, IL-4, and TNF receptor 1 mRNA
levels (P  0.01 to 0.001 versus controls).
Profiles of mRNAs for genes encoding signal transduction
molecules and others. Leukocytes in the blood of patients with
sepsis showed increased transcription of an array of genes
involved in signal transduction and coagulation (Table 4). Ac-
tivation of leukocytes by B. pseudomallei was reflected by in-
creased expression of mRNAs involved in the NF-B pathway
(those for NF-B1, NF-B2, and NF-B inhibitor 1) and of
mRNAs for cyclin-dependent kinase inhibitor 1A, glutathione
S-transferase (GSTP1), platelet-derived growth factor beta
polypeptide (PDGFB), protein-tyrosine phosphatases, serine
proteinase inhibitor (clade B, member 9) (SERPINB9), tissue
factor (TF), and thrombospondin (P  0.001 versus controls).
The relative contributions of monocytes and granulocytes to
the signal transduction and coagulation-specific inflammatory
mRNA profiles were separately analyzed. The majority of
genes that were found to be upregulated in unseparated leu-
kocytes were also upregulated in monocytes and granulocytes,
with a few exceptions. Increased expression of NF-B1 mRNA
could be detected only in the granulocyte-enriched population,
while the monocytes appeared to be the source for the upregu-
lated thrombospondin 1 mRNA levels (for both, P  0.001
versus controls). Some genes (those for GSTP1, NF-B subunit 1
[NF-B1], PDGFB, and TF) showed a modestly enhanced ex-
pression in total leukocytes, which was not detectable in either
monocyte- or granulocyte-enriched fractions.
Correlation with mortality. After characterizing the inflam-
matory mRNA profile, we sought to examine differences in the
mRNA profiles of leukocytes, monocytes, and granulocytes
between survivors and nonsurvivors of sepsis caused by B.
pseudomallei. Table 5 shows the mRNAs whose expression
displayed an association with mortality. In particular, mono-
cyte mRNA expression was associated with clinical outcome:
TABLE 2. Expression of proinflammatory cytokines and mediators
mRNA from
gene encoding
indicated product
Expression (mean  SEM)a in:
Leukocytes Granulocytes Monocytes
Controls Patients Controls Patients Controls Patients
IFN-	 0.032  0.002 0.083  0.022*** NDb ND 0.027  0.003 0.020  0.004
IL-12
 0.069  0.003 0.145  0.040 0.034  0.006 0.010  0.003** 0.048  0.006 0.044  0.007
IL-12 ND ND ND ND ND ND
IL-15-R01 0.066  0.004 0.275  0.046*** 0.013  0.003 0.110  0.016*** 0.072  0.062 0.136  0.012***
IL-15-R02 0.011  0.001 0.060  0.016*** ND ND 0.002  0.001 0.009  0.003*
IL-1
 ND ND ND ND ND ND
IL-1 0.191  0.013 0.346  0.030*** 0.153  0.014 0.236  0.029* 0.072  0.009 0.135  0.031
IL-2 ND ND ND ND ND ND
IL-6 0.018  0.002 0.095  0.046*** 0.000  0.000 0.018  0.007*** 0.003  0.001 0.002  0.001
IL-8 0.126  0.012 0.112  0.022 0.156  0.020 0.067  0.022*** 0.159  0.040 0.076  0.028***
TNF- 0.037  0.002 0.084  0.022** 0.003  0.002 0.004  0.004 0.038  0.004 0.024  0.003*
MCP-1 ND ND ND ND 0.009  0.002 0.002  0.001*
MCP-2 ND ND ND ND 0.001  0.001 0.004  0.002
MIP-1
 0.020  0.002 0.107  0.018*** 0.006  0.002 0.049  0.013* 0.013  0.002 0.067  0.023***
MIP-1 0.102  0.007 0.201  0.034** 0.062  0.005 0.089  0.015 0.137  0.009 0.170  0.052*
TNF 0.016  0.001 0.078  0.023*** 0.006  0.006 0.004  0.002 0.006  0.002 0.019  0.004**
a Expression of inflammatory mRNAs from patients and control subjects in whole-blood leukocytes, granulocytes, and monocytes (normalized to B2M mRNA and
in alphabetical order). P values are according to the Mann-Whitney test: *, P  0.05; **, P  0.01; ***, P  0.001 (versus controls).
b ND, not detectable.
TABLE 3. Expression of anti-inflammatory cytokines and mediators
mRNA from
gene encoding
indicated product
Expression (mean  SEM)a in:
Leukocytes Granulocytes Monocytes
Controls Patients Controls Patients Controls Patients
IL-1RA 0.307  0.021 0.730  0.099*** 0.384  0.033 0.667  0.071** 0.234  0.021 0.560  0.120***
IL-4 transcript variant 1 NDb ND ND ND ND ND
IL-4 transcript variant 2 0.011  0.001 0.093  0.040*** 0.000  0.000 0.015  0.005*** 0.000  0.000 0.048  0.022***
IL-10 0.014  0.001 0.144  0.001*** 0.006  0.006 0.014  0.005 0.000  0.000 0.015  0.004***
IL-13 ND ND ND ND ND ND
TNF receptor
superfamily 1A
0.406  0.019 0.770  0.058*** 0.280  0.031 0.553  0.068** 0.192  0.014 0.407  0.064**
a Expression of inflammatory mRNAs from patients and control subjects in whole-blood leukocytes, granulocytes, and monocytes (normalized to B2M mRNA and
in alphabetical order). P values are according to the Mann-Whitney test: **, P  0.01; ***, P  0.001 (versus controls).
b ND, not detectable.
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the IL-1, IL-1RA, MIP-1
, NF-B1, NF-B1A, and TNF
receptor 1 mRNAs were all significantly upregulated in the
monocytes of nonsurvivors (P  0.05 to 0.01 versus survivors).
Interestingly, SERPINB9 mRNA upregulation was associated
with a poor outcome only in granulocytes (P  0.05 for the
difference between survivors and nonsurvivors). There was no
significant relationship between the other analyzed inflamma-
tory mRNA levels and outcome (data not shown).
DISCUSSION
The host response to sepsis is multifactorial and its patho-
genesis complex. Analyses of gene expression patterns of blood
leukocytes in human sepsis will provide useful information on
what has been called the “sepsis transcriptome” (3, 6). Such
clinical studies might help us to gain new pathophysiological
insights and help patient stratification, which in turn may result
in more targeted and individualized therapeutic interventions.
Numerous studies have already characterized the plasma pro-
tein concentrations of inflammatory mediators in sepsis. Our
study is the first to perform an analysis of the inflammatory
mRNA profile in sepsis, looking at both monocyte and gran-
ulocyte cell fractions.
Suzuki et al. were the first to comprehensively analyze the
inflammatory gene expression profile of lipopolysaccharide-
stimulated human macrophages compared to resting mono-
cytes by using serial analysis of gene expression (20). Nau et al.
examined ex vivo gene expression patterns in differentiated
human macrophages in response to stimulation with different
pathogens and showed that macrophages responded to a broad
range of bacteria with a robust, shared pattern of gene expres-
sion (12). Furthermore, Feezor et al. characterized the inflam-
TABLE 4. Expression of signal transduction molecules and others
mRNA from
gene encoding
indicated product
Expression (mean  SEM)a in:
Leukocytes Granulocytes Monocytes
Controls Patients Controls Patients Controls Patients
BMI-1 oncogene homolog 0.106  0.005 0.130  0.023 0.030  0.005 0.036  0.009 0.149  0.010 0.115  0.009
Cyclin-dependent kinase
inhibitor 1A
0.048  0.002 0.160  0.024*** 0.008  0.003 0.046  0.009** 0.142  0.012 0.295  0.037***
GSTP1 0.029  0.002 0.086  0.022*** 0.004  0.002 0.004  0.002 0.046  0.004 0.044  0.005
v-Myc oncongene homolog 0.174  0.009 0.212  0.041 0.048  0.007 0.076  0.023 0.297  0.024 0.269  0.027
NF-B1 0.183  0.010 0.424  0.064*** 0.130  0.013 0.323  0.036*** 0.231  0.011 0.320  0.037
NF-B2 0.025  0.002 0.100  0.026*** 0.004  0.002 0.016  0.005 0.004  0.001 0.015  0.005
NF-B inhibitor alpha 0.212  0.012 0.835  0.086*** 0.151  0.015 0.570  0.076*** 0.190  0.009 0.662  0.155***
Polyadenylate-specific RNase 0.160  0.006 0.214  0.034 0.087  0.0006 0.109  0.014 0.176  0.012 0.153  0.013
Phosphodiesterase 4B, cyclic
AMP specific
0.266  0.012 0.387  0.042 0.257  0.022 0.347  0.032 0.256  0.014 0.251  0.041
PDGFB 0.024  0.001 0.117  0.048*** NDb ND 0.024  0.003 0.017  0.003
Protein-tyrosine phosphatase,
type 4A, 2
0.709  0.023 1.0230  0.053*** 0.423  0.033 0.972  0.111*** 0.929  0.051 1.218  0.095*
Protein-tyrosine phosphatase,
nonreceptor type, 1
0.040  0.002 0.132  0.023*** 0.022  0.004 0.054  0.009* 0.055  0.004 0.094  0.012**
TF 0.010  0.001 0.0870  0.047*** ND ND ND ND
SERPINB9 0.201  0.010 0.451  0.069*** 0.080  0.008 0.205  0.0036* 0.314  0.022 0.422  0.065
Thrombospondin 1 0.026  0.002 0.096  0.023*** 0.004  0.002 0.016  0.007 0.052  0.006 0.156  0.025***
a Expression of inflammatory mRNAs from patients and control subjects in whole-blood leukocytes, granulocytes, and monocytes (normalized to B2M mRNA and
in alphabetical order). P values are according to the Mann-Whitney test: *, P  0.05; **, P  0.01; ***, P  0.001 (versus controls).
b ND, not detectable.
TABLE 5. Correlation between monocyte and granulocyte inflammatory mRNA expression and mortality in patients with
sepsis caused by B. pseudomallei
mRNA from
gene encoding
indicated product
Expression (mean  SEM)a in:
Leukocytes Granulocytes Monocytes
Survivors Nonsurvivors Survivors Nonsurvivors Survivors Nonsurvivors
IL-1 0.318  0.025 0.291  0.050 0.237  0.028 0.244  0.071 0.088  0.023 0.202  0.073*
IL-1RA 0.562  0.043 0.773  0.135 0.708  0.093 0.670  0.145 0.414  0.098 0.827  0.287*
IL-15-R01 0.250  0.073 0.266  0.029* 0.097  0.022 0.149  0.026 0.118  0.012 0.182  0.038
MIP-1
 0.067  0.009 0.110  0.022 0.038  0.017 0.048  0.019 0.024  0.004 0.115  0.059*
NF-B1 0.300  0.016 0.378  0.046 0.330  0.048 0.379  0.068 0.264  0.039 0.434  0.075*
NF-B inhibitor alpha 0.548  0.054 1.089  0.168** 0.543  0.088 0.676  0.156 0.377  0.115 1.134  0.359**
TNF receptor superfamily 1A 0.718  0.052 0.782  0.106 0.594  0.092 0.600  0.295 0.346  0.076 0.553  0.127*
SERPINB9 0.247  0.029 0.402  0.097 0.155  0.047 0.315  0.069* 0.351  0.062 0.552  0.150
a Expression of inflammatory mRNAs from survivors (n  20) and nonsurvivors (n  14) in whole-blood leukocytes, granulocytes, and monocytes (normalized to
B2M mRNA and in alphabetical order). Only the inflammatory mRNAs with a significant relation to outcome are shown. P values are according to the Mann-Whitney
test: *, P  0.05; **, P  0.01 (versus survivors).
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matory gene expression profile of leukocytes stimulated ex vivo
with gram-negative and gram-positive bacteria, demonstrating
that the host inflammatory responses to gram-negative and
gram-positive stimuli share some common response elements
but, more importantly, exhibit distinct patterns of leukocyte
gene expression (6, 7). Lipopolysaccharide (endotoxin) is the
major virulence factor in gram-negative bacteria, and a recent
study on the changes in blood leukocyte gene expression pat-
terns in a human endotoxin model sheds lights on the effect
that this causes in humans (3). Calvano et al. intravenously
administered endotoxin at a dose of 2 ng/kg in eight healthy
volunteers and, using a network-based analysis of systemic
inflammation, found that the human blood leukocyte response
to acute systemic inflammation includes the transient dysregu-
lation of leukocyte bioenergetics and modulation of transla-
tional machinery (3). In their discussion, Calvano et al. stress
the importance of the further identification of specific cell
populations showing changes in inflammatory gene expression,
which will require the isolation and enrichment of specific
leukocyte subpopulations (3). Our study is the first of its kind
to use gene expression profiling to obtain insights into the
systemic inflammatory status of both monocytes and granulo-
cytes during human sepsis.
Part of our data confirm and extend previous studies. In a
heterogeneous cohort of patients with septic shock, Pachot et
al. also found increased levels of IL-1 mRNA in the leuko-
cytes of patients with sepsis compared to healthy controls (14).
In addition, the inflammatory gene expression profile of mono-
cytes in our study confirmed the earlier ex vivo data presented
by Suzuki et al. (20) and Nau et al. (12), who also showed an
upregulation of genes encoding TNF-
, IL-8, MCP-1, MIP-1
,
and MIP-1 in monocytes and macrophages stimulated with
lipopolysaccharide or various bacteria. The marked proinflam-
matory response that occurs in sepsis is balanced by the acti-
vation of counterregulatory pathways, as illustrated by the re-
lease of anti-inflammatory cytokines (5, 8, 21). Indeed, in our
patient population we observed a uniform upregulation of
mRNAs encoding anti-inflammatory cytokines and cytokine
antagonists such as IL-4, IL-10, IL-1RA, and TNF receptor 1,
in addition to upregulation of the proinflammatory cytokine
mRNAs. This finding suggests that upregulation of IL-4 and
IL-10 is insufficient to counter the proinflammatory conse-
quences of sepsis caused by B. pseudomallei.
It is conceivable that in the not-too-distant future, mRNA
expression profiles will be used for the identification of patients
with sepsis who might benefit from a specific intervention. We
show that high IL-1, IL-1RA, MIP-1
, NF-B1, NF-B1A,
and TNF receptor 1 mRNA levels in monocytes are correlated
with poor outcome. In a study that sought to determine gene
expression in monocyte-enriched populations in association
with clinical outcome for patients with multiple blunt trauma,
the IL-1 gene was among the genes associated with a poor
outcome (2). However, in our population of patients with sep-
sis due to melioidosis, we could not confirm the finding of
another study, in which increased expression of IL-10 mRNA
in leukocytes was correlated (and that of IL-1 mRNA was
not) with mortality in a heterogeneous population of patients
with septic shock (14), highlighting the diverse nature of sepsis.
The pattern of gene expression in patients who died suggests
that in these individuals, there is a reprioritization of gene
expression consistent with an early activation of selected genes
involved in the initiation and propagation of a proinflamma-
tory response (2). Given the fact that almost two-thirds of our
patients had positive blood cultures for B. pseudomallei, it was
possible to investigate potential differences in inflammatory
mRNA profile between patients with bacteremic and nonbac-
teremic melioidosis. However, no significant difference in the
inflammatory mRNA profile was seen between these two
groups (data not shown), suggesting that the overall systemic
inflammatory response as measured in whole-blood leuko-
cytes, granulocytes, and monocytes is not greatly influenced by
the detection of bacteria in the bloodstream in patients with
sepsis.
The plasma levels of IL-6 and IL-8 are almost invariably
strongly elevated in patients with severe sepsis (including mel-
ioidosis) (18, 23). Notably, using MLPA, the mRNAs encoding
these two cytokines were found to be not increased (IL-8) or to
be only minimally increased (IL-6) in circulating leukocytes.
These data strongly suggest that cells not present in blood are
the major producers of IL-6 and IL-8 in sepsis, with endothe-
lial cells and tissue macrophages being likely candidates. The
expression of some genes was enhanced in the whole-blood
leukocytes but not in either monocyte- or granulocyte-enriched
fractions. This suggests that lymphocytes are the source of
some mRNAs in whole-blood leukocytes. Indeed, lymphocytes
are a major source for IFN-	, of which modestly elevated
mRNA levels were detected in blood leukocytes but not in
monocytes or granulocytes. The mRNA encoding TF, which is
considered to be the initiator of coagulation activation in sepsis
(9), was detected at low levels in leukocytes of patients and
controls but was at a significantly higher level in the former.
The fact that TF mRNA levels were not detectable in mono-
cytes or granulocytes may, especially in monocytes, be related
to the limit of detection of the MLPA used. Of note, TF may
in addition be produced by cell types not present in blood, in
particular endothelial cells and macrophages (9).
Our study has several limitations. Our observations were
done with patients with culture-proven melioidosis, and cau-
tion is required when extending these findings to sepsis in
general. In this respect it should be noted that gram-positive
and gram-negative pathogens elicit distinct patterns of leuko-
cyte gene expression in vitro (6, 7). In addition, during the
inflammatory response to invading pathogens, it is likely that
the expression of inflammatory genes alters over time. We
focused on the early phase of sepsis and only included patients
as early as possible after hospital admission. Furthermore, it
has to be noted that there was an age difference between the
patient and control groups, which is due to the fact that it is
difficult to obtain blood from healthy older people living in
Ubon Ratchathani, Thailand. We consider it unlikely, how-
ever, that this factor significantly influenced our main re-
sults, considering the relatively large differences between
patients and controls. Obtaining new biological insights
from high-throughput genomic studies of human diseases is
a challenge, limited by difficulties in recognizing and evalu-
ating relevant biological processes from large quantities of
experimental data (3).
In conclusion, this study presents the direct measurement of
molecular signatures from more than 30 inflammatory genes in
the leukocytes, granulocytes, and monocytes of a cohort of
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patients with sepsis caused by B. pseudomallei. Our data un-
derline the notion that circulating leukocytes are an important
source for inflammatory mediators in patients with gram-neg-
ative sepsis. Moreover, gene profiling such as done here by
MLPA provides an excellent tool to obtain insight into the
extent of inflammation activation in patients with severe
infection.
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